Regencell bioscience's standardized formulae are shown to reduce adhd and asd symptoms in the interim results of its second efficacy trial

Hong kong--(business wire)---- $rgc #adhd--regencell bioscience holdings limited (nasdaq: rgc) (“regencell”) today announced its interim results from its second efficacy trial. regencell conducted its second efficacy trial using standardized traditional chinese medicine (“tcm”) formulae. “our aim is to save and improve lives by making our standardized tcm formulae widely available to adhd and asd patients around the world. it is known that there is a significant economic impact and increased parental burden t
RGC Ratings Summary
RGC Quant Ranking